article 3D bioprinting COVID-19 lung models for drug development 19 June 2020 | By Hannah Balfour (Drug Target Review) Keith Murphy, CEO of Viscient Biosciences, discusses the process of developing a 3D bioprinted tissue model and their potential in developing therapeutics for COVID-19 and other diseases.